Dr. Faubert leads a research laboratory focused on understanding how metabolic reprogramming—alterations in metabolic flux within malignant cells—supports cancer cell survival, growth, and progression. The Faubert lab has extensive expertise in both in vitro and in vivo metabolic analysis, including the direct measurement of tumor metabolism intra-operatively in patients.
To achieve a comprehensive understanding of metabolic pathways in cancer, Dr. Faubert's team employs a wide array of mass spectrometry platforms alongside advanced methodologies such as isotope tracing (^13C, ^2H, etc.), metabolomics, and metabolic flux analysis. These tools allow the lab to dissect the metabolic programs driving malignant phenotypes at both cellular and systemic levels.
Complementing these biochemical techniques, the lab also uses molecular imaging technologies to noninvasively monitor tumor metabolic states in vivo. This dual approach enables the investigation of metabolic heterogeneity across different tumor types and stages. Recent work from Dr. Faubert’s laboratory is exploring the metabolic alterations that occur during the metastatic cascade, aiming to uncover novel vulnerabilities that can be therapeutically targeted.
UT Southwestern
Dallas
Postdoc - Cancer Metabolism
2021
McGill University
Montreal
PhD - Physiology
2015
Approaches to stable isotope tracing and in vivo metabolomics in the cancer clinic.
Approaches to stable isotope tracing and in vivo metabolomics in the cancer clinic. EMBO J. 2025 May 12.
PMID: 40355557
High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non-Small Cell Lung Cancer in Patients.
High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non-Small Cell Lung Cancer in Patients. Cancer Discov. 2025 Apr 02; 15(4):702-716.
PMID: 39960461
Concurrent loss of LKB1 and KEAP1 enhances SHMT-mediated antioxidant defence in KRAS-mutant lung cancer.
Concurrent loss of LKB1 and KEAP1 enhances SHMT-mediated antioxidant defence in KRAS-mutant lung cancer. Nat Metab. 2024 Jul; 6(7):1310-1328.
PMID: 38877143
Electron transport chain inhibition increases cellular dependence on purine transport and salvage.
Electron transport chain inhibition increases cellular dependence on purine transport and salvage. Cell Metab. 2024 Jul 02; 36(7):1504-1520.e9.
PMID: 38876105
Severely polarized extracellular acidity around tumour cells.
Severely polarized extracellular acidity around tumour cells. Nat Biomed Eng. 2024 Jun; 8(6):787-799.
PMID: 38438799
Metabolic signatures of thymomas: potential biomarkers and treatment targets.
Metabolic signatures of thymomas: potential biomarkers and treatment targets. Eur J Cardiothorac Surg. 2024 Feb 01; 65(2).
PMID: 38011656
Metabolic Signatures of Thymomas: Potential Biomarkers and Treatment Targets.
Metabolic Signatures of Thymomas: Potential Biomarkers and Treatment Targets. Eur J Cardiothorac Surg. 2023 Nov 27.
PMID: 38011656
Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity.
Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity. Nature. 2023 Nov; 623(7989):1034-1043.
PMID: 37993715
Metabolic pathway analysis using stable isotopes in patients with cancer.
Metabolic pathway analysis using stable isotopes in patients with cancer. Nat Rev Cancer. 2023 Dec; 23(12):863-878.
PMID: 37907620
Adipocytes reprogram cancer cell metabolism by diverting glucose towards glycerol-3-phosphate thereby promoting metastasis.
Adipocytes reprogram cancer cell metabolism by diverting glucose towards glycerol-3-phosphate thereby promoting metastasis. Nat Metab. 2023 09; 5(9):1563-1577.
PMID: 37653041